2025-01-31 - Analysis Report
## Starbucks Corp (SBUX) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO):**

Starbucks Corp (SBUX) is a multinational chain of coffeehouses and roastery reserves.  The cumulative return of SBUX is 71.10%, while the S&P 500 (VOO) shows a cumulative return of 121.09%.  Therefore, SBUX has underperformed VOO by 49.99 percentage points as of the last day of the data provided.  The relative divergence indicates SBUX's performance is in the 31.2th percentile relative to its historical performance against the VOO.  While the Alpha consistently hovers around 0.1, indicating marginal outperformance, the Beta (significantly above 1) highlights SBUX's high sensitivity to market fluctuations.  The CAGR shows considerable volatility, ranging from substantial gains to notable losses year-over-year, suggesting a high-risk investment.


**2. Recent Price Movement:**

* **Closing Price:** $109.0
* **5-Day Moving Average:** $103.36
* **20-Day Moving Average:** $96.33
* **60-Day Moving Average:** $96.73

The price is above all three moving averages, suggesting a short-term uptrend. The significant gap between the current price and the 20 and 60-day moving averages highlights the recent price surge.


**3. Technical Indicators and Expected Return:**

* **RSI:** 94.37 –  Extremely overbought, indicating a high probability of a price correction.
* **PPO:** 1.71 – Positive, suggesting bullish momentum, but needs to be viewed in the context of the extremely overbought RSI.
* **20-Day Relative Divergence:** +13.2 – Shows a recent short-term upward trend.
* **Expected Return:** -31.6% – This suggests a significant underperformance compared to the S&P 500 over the long term (2+ years), assuming current trends continue.  The price change of $0.38 indicates a modest upward movement, not a dramatic spike.

**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2025-01-28 | $0.69  | $9.40B      |
| 2024-07-30 | $0.93  | $9.11B      |
| 2024-04-30 | $0.68  | $8.56B      |
| 2024-01-30 | $0.90  | $9.43B      |
| 2023-12-31 | $0.90  | $9.43B      | *(Duplicate entry assumed to be corrected)*


Earnings show some volatility, with EPS fluctuating between $0.68 and $0.93. Revenue remains relatively stable around $9B, indicating consistent sales.  Further analysis is required to determine trends and factors affecting earnings.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-12-31 | $9.40B      | 24.49%        |
| 2024-09-30 | $9.07B      | 26.25%        |
| 2024-06-30 | $9.11B      | 27.91%        |
| 2024-03-31 | $8.56B      | 25.58%        |
| 2023-12-31 | $9.43B      | 27.51%        |

Revenue is relatively consistent, but profit margins show some fluctuation.  Further investigation is needed to understand the underlying reasons.

**Capital and Profitability:**

| Quarter | Equity      | ROE           |
|---------|-------------|---------------|
| 2024-12-31 | $-7.47B     | -10.45%       |
| 2024-09-30 | $-7.45B     | -12.21%       |
| 2024-06-30 | $-7.95B     | -13.28%       |
| 2024-03-31 | $-8.45B     | -9.14%        |
| 2023-12-31 | $-8.62B     | -11.89%       |

Negative equity is a significant concern, indicating the company may have more liabilities than assets. The negative ROE further emphasizes this weak financial position.


**7. Overall Analysis:**

SBUX's recent price surge has pushed its RSI into overbought territory, signaling potential short-term correction. While recent price action is positive and some earnings remain strong, the negative equity and ROE, coupled with the significant underperformance relative to the S&P 500 and the negative long-term expected return, present substantial risks.  Investors should carefully consider these factors before investing in SBUX.  Further investigation into the reasons for negative equity and the volatility in EPS is crucial for a comprehensive assessment.  The high beta also underscores the heightened risk associated with this stock.


**8. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Consult with a financial professional before making any investment decisions.
